Nps Pharms Inc patents expiration
1. Gattex Kit patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7056886 | NPS PHARMS INC | GLP-2 formulations |
Sep, 2022
(1 year, 6 days ago) | |
|
US7056886 (Pediatric) | NPS PHARMS INC | GLP-2 formulations |
Mar, 2023
(6 months ago) | |
| US9539310 | NPS PHARMS INC | Treatment of short bowel syndrome patients with colon-in-continuity |
Nov, 2025
(2 years from now) | |
| US9974835 | NPS PHARMS INC | Treatment of short bowel syndrome patients with colon-in-continuity |
Nov, 2025
(2 years from now) | |
| US9555079 | NPS PHARMS INC | Treatment of short bowel syndrome patients with colon-in-continuity |
Nov, 2025
(2 years from now) | |
| US9987334 | NPS PHARMS INC | Treatment of short bowel syndrome patients with colon-in-continuity |
Nov, 2025
(2 years from now) | |
| US9060992 | NPS PHARMS INC | Treatment of short bowel syndrome patients with colon-in-continuity |
Nov, 2025
(2 years from now) | |
| US9981016 | NPS PHARMS INC | Treatment of short bowel syndrome patients with colon-in-continuity |
Nov, 2025
(2 years from now) | |
| US9968656 | NPS PHARMS INC | Treatment of short bowel syndrome patients with colon-in-continuity |
Nov, 2025
(2 years from now) | |
| US9987335 | NPS PHARMS INC | Treatment of short bowel syndrome patients with colon-in-continuity |
Nov, 2025
(2 years from now) | |
| US9592274 | NPS PHARMS INC | Treatment of short bowel syndrome patients with colon-in-continuity |
Nov, 2025
(2 years from now) | |
| US9974837 | NPS PHARMS INC | Treatment of short bowel syndrome patients with colon-in-continuity |
Nov, 2025
(2 years from now) | |
| US9981014 | NPS PHARMS INC | Treatment of short bowel syndrome patients with colon-in-continuity |
Nov, 2025
(2 years from now) | |
| US7847061 | NPS PHARMS INC | Treatment of short bowel syndrome patients with colon-in-continuity |
Nov, 2025
(2 years from now) | |
| US9545434 | NPS PHARMS INC | Treatment of short bowel syndrome patients with colon-in-continuity |
Nov, 2025
(2 years from now) | |
| US9968655 | NPS PHARMS INC | Treatment of short bowel syndrome patients with colon-in-continuity |
Nov, 2025
(2 years from now) | |
| US9572867 | NPS PHARMS INC | Treatment of short bowel syndrome patients with colon-in-continuity |
Nov, 2025
(2 years from now) | |
| US9993528 | NPS PHARMS INC | Treatment of short bowel syndrome patients with colon-in-continuity |
Nov, 2025
(2 years from now) | |
| US9968658 | NPS PHARMS INC | Treatment of short bowel syndrome patients with colon-in-continuity |
Nov, 2025
(2 years from now) | |
| US9545435 | NPS PHARMS INC | Treatment of short bowel syndrome patients with colon-in-continuity |
Nov, 2025
(2 years from now) | |
| US9592273 | NPS PHARMS INC | Treatment of short bowel syndrome patients with colon-in-continuity |
Nov, 2025
(2 years from now) | |
|
US9555079 (Pediatric) | NPS PHARMS INC | Treatment of short bowel syndrome patients with colon-in-continuity |
May, 2026
(2 years from now) | |
|
US7847061 (Pediatric) | NPS PHARMS INC | Treatment of short bowel syndrome patients with colon-in-continuity |
May, 2026
(2 years from now) | |
|
US9060992 (Pediatric) | NPS PHARMS INC | Treatment of short bowel syndrome patients with colon-in-continuity |
May, 2026
(2 years from now) | |
|
US9592274 (Pediatric) | NPS PHARMS INC | Treatment of short bowel syndrome patients with colon-in-continuity |
May, 2026
(2 years from now) | |
|
US9592273 (Pediatric) | NPS PHARMS INC | Treatment of short bowel syndrome patients with colon-in-continuity |
May, 2026
(2 years from now) | |
|
US9572867 (Pediatric) | NPS PHARMS INC | Treatment of short bowel syndrome patients with colon-in-continuity |
May, 2026
(2 years from now) | |
|
US9987335 (Pediatric) | NPS PHARMS INC | Treatment of short bowel syndrome patients with colon-in-continuity |
May, 2026
(2 years from now) | |
|
US9993528 (Pediatric) | NPS PHARMS INC | Treatment of short bowel syndrome patients with colon-in-continuity |
May, 2026
(2 years from now) | |
|
US9981016 (Pediatric) | NPS PHARMS INC | Treatment of short bowel syndrome patients with colon-in-continuity |
May, 2026
(2 years from now) | |
|
US9968658 (Pediatric) | NPS PHARMS INC | Treatment of short bowel syndrome patients with colon-in-continuity |
May, 2026
(2 years from now) | |
|
US9974837 (Pediatric) | NPS PHARMS INC | Treatment of short bowel syndrome patients with colon-in-continuity |
May, 2026
(2 years from now) | |
|
US9968656 (Pediatric) | NPS PHARMS INC | Treatment of short bowel syndrome patients with colon-in-continuity |
May, 2026
(2 years from now) | |
|
US9968655 (Pediatric) | NPS PHARMS INC | Treatment of short bowel syndrome patients with colon-in-continuity |
May, 2026
(2 years from now) | |
|
US9987334 (Pediatric) | NPS PHARMS INC | Treatment of short bowel syndrome patients with colon-in-continuity |
May, 2026
(2 years from now) | |
|
US9981014 (Pediatric) | NPS PHARMS INC | Treatment of short bowel syndrome patients with colon-in-continuity |
May, 2026
(2 years from now) | |
|
US9539310 (Pediatric) | NPS PHARMS INC | Treatment of short bowel syndrome patients with colon-in-continuity |
May, 2026
(2 years from now) | |
|
US9545435 (Pediatric) | NPS PHARMS INC | Treatment of short bowel syndrome patients with colon-in-continuity |
May, 2026
(2 years from now) | |
|
US9545434 (Pediatric) | NPS PHARMS INC | Treatment of short bowel syndrome patients with colon-in-continuity |
May, 2026
(2 years from now) | |
|
US9974835 (Pediatric) | NPS PHARMS INC | Treatment of short bowel syndrome patients with colon-in-continuity |
May, 2026
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | May 16, 2026 |
Drugs and Companies using TEDUGLUTIDE RECOMBINANT ingredient
Market Authorisation Date: 21 December, 2012
Treatment: Treatment of adult patients with short bowel syndrome who are dependent on parenteral support
Dosage: POWDER;SUBCUTANEOUS
GATTEX KIT family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic